Patients with paradoxical articular manifestation, n= 17 (%) | Patients without new inflammatory articular manifestation, n=322 (%) | P value | |
Female gender, n (%) | 11 (64.7) | 142 (44.1) | 0.133 |
Male gender, n (%) | 6 (35.3) | 180 (55.9) | 0.133 |
Age (years), mean (SD) | 31.4 (10.9) | 36.2 (15.6) | 0.329 |
Inflammatory bowel disease | |||
Crohn disease, n (%) | 9 (52.9) | 195 (60.6) | 0.614 |
Ulcerative colitis, n (%) | 8 (47.1) | 118 (36.6) | 0.443 |
Indeterminate colitis, n (%) | 0 (0) | 9 (2.8) | 1 |
Disease duration (years), mean | 6.9 (7.6) | 5.8 (7.4) | 0.658 |
Psoriasis, n (%) | 0 (0) | 5 (1.6) | 1 |
Paradoxical psoriasis, n (%) | 1 (5.9) | 14 (4.3) | 0.546 |
Uveitis, n (%) | 0 (0) | 1 (0.3) | 1 |
No of anti-TNFa received, mean (SD) | 1.5 (0.7) | 1.4 (0.6) | 0.377 |
Immunosuppressive therapy at the beginning of anti-TNFa, n (%) | |||
Azathioprine, n (%) | 11 (64.7) | 197 (61.2) | 1 |
Methotrexate, n (%) | 11 (64.7) | 162 (50.3) | 0.322 |
Purinethol, n (%) | 0 (0) | 12 (3.7) | 1 |
Others, n (%) | 0 (0) | 21 (6.5) | 0.612 |
Anti TNF Abs | 0 (0) | 2 (0.6) | 1 |
Positive, n (%) | 0 (0) | 33 (10.2) | 0.39 |
Follow-up, mean, years (SD) | 6.5 (3.3) | 5.1 (2.8) | 0.063 |
Total anti-TNFa duration, mean, years (SD) | 5.6 (3.0) | 3,3 (2.6) | 0.00002 |
TNF, tumour necrosis factor.